OT mobile menu

Search form



Subcutaneous Rituximab May Soon Be Approved for Certain Blood Cancers

Study suggests that intravenous and subcutaneous rituximab share similar efficacy and safety profiles. Image © Neramit Buakaew/Shutterstock.com

Recent Content

A 43-year-old man presents with a nodule in the right upper chest wall area. After a biopsy is performed, what is your diagnosis?

A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.

Vaccination with the immune complement component C3d protein blocks tumor-mediated immunosuppression, enhancing antitumor immune response.

Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.

Researchers at Weill Cornell Medicine are reporting that they have successfully converted cells from blood vessels in mice into blood-forming stem cells.

A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.

We spoke with Monica Fradkin on ways to help minimize adverse events in patients receiving immunotherapy treatment at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.

By clicking Accept, you agree to become a member of the UBM Medica Community.